Category: Press Release - Page 17 - Psychedelic Alpha

Read more about the article MIND CURE AND LNG ENERGY GROUP ENTER INTO ARRANGEMENT AGREEMENT WITH RESPECT TO PREVIOUSLY ANNOUNCED BUSINESS COMBINATION TRANSACTION

MIND CURE AND LNG ENERGY GROUP ENTER INTO ARRANGEMENT AGREEMENT WITH RESPECT TO PREVIOUSLY ANNOUNCED BUSINESS COMBINATION TRANSACTION

Post published:May 6, 2023
Post category:Press Release

Read more about the article Algernon Pharmaceuticals Announces Closing of Rights Offering

Algernon Pharmaceuticals Announces Closing of Rights Offering

Post published:May 6, 2023
Post category:Press Release

Read more about the article Optimi Health Announces CAD$1.2 Million GMP Psilocybin Supply Agreement for Clinical Research and Development

Optimi Health Announces CAD$1.2 Million GMP Psilocybin Supply Agreement for Clinical Research and Development

Post published:May 4, 2023
Post category:Press Release

Read more about the article COMPASS Pathways plc to announce first quarter 2023 financial results on 11 May 2023

COMPASS Pathways plc to announce first quarter 2023 financial results on 11 May 2023

Post published:May 3, 2023
Post category:Press Release

Read more about the article Small Pharma to Present at Upcoming CINP World Congress of Neuropsychopharmacology

Small Pharma to Present at Upcoming CINP World Congress of Neuropsychopharmacology

Post published:May 3, 2023
Post category:Press Release

Read more about the article atai Life Sciences to Participate in Upcoming May Investor Conference

atai Life Sciences to Participate in Upcoming May Investor Conference

Post published:May 3, 2023
Post category:Press Release

Read more about the article Clearmind Medicine Announces Clinical Supply Agreement for its Upcoming Clinical Trial

Clearmind Medicine Announces Clinical Supply Agreement for its Upcoming Clinical Trial

Post published:May 2, 2023
Post category:Press Release

Read more about the article PharmaTher Holdings Submits Fast Track Application to FDA for KETARX™ (Ketamine) for the Treatment of Parkinson’s Disease

PharmaTher Holdings Submits Fast Track Application to FDA for KETARX™ (Ketamine) for the Treatment of Parkinson’s Disease

Post published:May 2, 2023
Post category:Press Release

Read more about the article American Medical Association to Issue First New Code for Psychedelic Therapies

American Medical Association to Issue First New Code for Psychedelic Therapies

Post published:May 2, 2023
Post category:Press Release

Read more about the article Revive Therapeutics Announces Data Safety Monitoring Board Meeting Date on Phase 3 Clinical Study of Bucillamine in the Treatment of COVID-19

Revive Therapeutics Announces Data Safety Monitoring Board Meeting Date on Phase 3 Clinical Study of Bucillamine in the Treatment of COVID-19

Post published:May 2, 2023
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.